NCT00775229

Naltrexone in the Treatment of Trichotillomania

A Double-blind, Placebo-controlled Study of Naltrexone in Trichotillomania

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 51 (actual)
• Sponsor: University of Chicago · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is an 8-week, double-blind study of Natrexone in the treatment of trichotillomania

Detailed description

The goal of the proposed study is to evaluate the efficacy of Naltrexone in trichotillomania. Forty subjects with DSM-IV trichotillomania will receive 8 weeks of double-blind Naltrexone or placebo. The hypothesis to be tested is that Naltrexone will be effective and well tolerated in patients with trichotillomania compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder that currently lacks a clearly effective treatment.

Conditions

• Trichotillomania

Interventions

Type	Name	Description
DRUG	Naltrexone	pill, by mouth, 50mg-150mg/day for the duration of the study
DRUG	Placebo	pill, by mouth, daily

Timeline

• Start date: 2008-08-01
• Primary completion: 2012-11-01
• Completion: 2012-12-01
• First posted: 2008-10-20
• Last updated: 2023-02-23
• Results posted: 2014-03-17

Locations

1 site across 1 country: United States